185 related articles for article (PubMed ID: 37157005)
1. Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer.
Sathe C; Accordino MK; DeStephano D; Shah M; Wright JD; Hershman DL
Breast Cancer Res Treat; 2023 Jul; 200(1):85-92. PubMed ID: 37157005
[TBL] [Abstract][Full Text] [Related]
2. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
Martin JM; Handorf EA; Montero AJ; Goldstein LJ
Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
[TBL] [Abstract][Full Text] [Related]
3. Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors.
Schreier A; Munoz-Arcos L; Alvarez A; Sparano JA; Anampa JD
Breast Cancer Res Treat; 2022 Jul; 194(2):337-351. PubMed ID: 35633421
[TBL] [Abstract][Full Text] [Related]
4. Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
Alvarez A; Bernal AM; Anampa J
Breast Cancer Res Treat; 2023 Feb; 198(1):75-88. PubMed ID: 36562909
[TBL] [Abstract][Full Text] [Related]
5. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
[TBL] [Abstract][Full Text] [Related]
6. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
[TBL] [Abstract][Full Text] [Related]
7. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
[TBL] [Abstract][Full Text] [Related]
9. Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis.
Kubeczko M; Jarząb M; Gabryś D; Krzywon A; Cortez AJ; Xu AJ
Radiother Oncol; 2023 Oct; 187():109839. PubMed ID: 37536378
[TBL] [Abstract][Full Text] [Related]
10. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
[TBL] [Abstract][Full Text] [Related]
11. First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study.
Basile D; Gerratana L; Corvaja C; Pelizzari G; Franceschin G; Bertoli E; Palmero L; Zara D; Alberti M; Buriolla S; Da Ros L; Bonotto M; Mansutti M; Spazzapan S; Cinausero M; Minisini AM; Fasola G; Puglisi F
Breast; 2021 Jun; 57():104-112. PubMed ID: 33812267
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real world.
Kruse M; Smyth EN; Bowman L; Gautam S; Guimaraes CM; Nisbett AR; Fisher MD; Cui ZL; Sheffield KM; Kalinsky K
Breast Cancer Res Treat; 2023 Aug; 201(1):105-115. PubMed ID: 37310540
[TBL] [Abstract][Full Text] [Related]
13. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study.
Goyal RK; Chen H; Abughosh SM; Holmes HM; Candrilli SD; Johnson ML
Cancer; 2023 Apr; 129(7):1051-1063. PubMed ID: 36760031
[TBL] [Abstract][Full Text] [Related]
14. Retrospective registry of patients with locally advanced/metastatic HR
Chavarría Piudo N; Blancas I; González Flores E; Henao Carrasco F; López Álvarez P; Morales Pancorbo D; Gámez Casado S; Lomas Garrido MC; Rodríguez García JM; Martínez Guisado A; Sánchez Vega A; Ruíz Borrego M
Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38831191
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
Gerratana L; Davis AA; Velimirovic M; Reduzzi C; Clifton K; Bucheit L; Hensing WL; Shah AN; Pivetta T; Dai CS; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Ma CX; Puglisi F; Bardia A; Cristofanilli M
JCO Precis Oncol; 2023 May; 7():e2200531. PubMed ID: 37141549
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
[TBL] [Abstract][Full Text] [Related]
17. CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis.
Müller C; Kiver V; Solomayer EF; Wagenpfeil G; Neeb C; Blohmer JU; Abramian AV; Maass N; Schütz F; Kolberg-Liedtke C; Ralser DJ; Rambow AC
Breast Care (Basel); 2023 Feb; 18(1):31-41. PubMed ID: 36876172
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis.
Behrouzi R; Armstrong AC; Howell SJ
Breast Cancer Res Treat; 2023 Nov; 202(1):83-95. PubMed ID: 37584881
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies.
Harbeck N; Bartlett M; Spurden D; Hooper B; Zhan L; Rosta E; Cameron C; Mitra D; Zhou A
Future Oncol; 2021 Jun; 17(16):2107-2122. PubMed ID: 33663223
[No Abstract] [Full Text] [Related]
20. CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?
Sakach E; Keskinkilic M; Wood S; Canning M; Kalinsky K
Curr Treat Options Oncol; 2023 Sep; 24(9):1103-1119. PubMed ID: 37314645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]